Long-term HPV-specific immune response after one versus two and three doses of bivalent HPV vaccination in Dutch girls.

[1]  S. Chanock,et al.  Evidence for single-dose protection by the bivalent HPV vaccine—Review of the Costa Rica HPV vaccine trial and future research studies , 2018, Vaccine.

[2]  D. Lowy,et al.  Explanations for the high potency of HPV prophylactic vaccines , 2018, Vaccine.

[3]  M. Pawlita,et al.  Can a single dose of human papillomavirus (HPV) vaccine prevent cervical cancer? Early findings from an Indian study. , 2018, Vaccine.

[4]  S. Garland,et al.  Cellular Immune Responses 6 Years Following 1, 2, or 3 Doses of Quadrivalent HPV Vaccine in Fijian Girls and Subsequent Responses to a Dose of Bivalent HPV Vaccine , 2018, Open forum infectious diseases.

[5]  M. Gail,et al.  Durability of Protection Afforded by Fewer Doses of the HPV16/18 Vaccine: The CVT Trial , 2018, Journal of the National Cancer Institute.

[6]  E. Sanders,et al.  Whole-cell or acellular pertussis vaccination in infancy determines IgG subclass profiles to DTaP booster vaccination. , 2018, Vaccine.

[7]  A. Wald,et al.  Analysis of Memory B-Cell Responses Reveals Suboptimal Dosing Schedule of a Licensed Vaccine , 2017, The Journal of infectious diseases.

[8]  H. D. de Melker,et al.  Immune Responses After 2 Versus 3 Doses of HPV Vaccination up to 4½ Years After Vaccination: An Observational Study Among Dutch Routinely Vaccinated Girls , 2016, The Journal of infectious diseases.

[9]  S. H. van der Burg,et al.  Vaccination against Oncoproteins of HPV16 for Noninvasive Vulvar/Vaginal Lesions: Lesion Clearance Is Related to the Strength of the T-Cell Response , 2016, Clinical Cancer Research.

[10]  P. Hillemanns,et al.  Sustained immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine administered as a two-dose schedule in adolescent girls: Five-year clinical data and modeling predictions from a randomized study , 2015, Human vaccines & immunotherapeutics.

[11]  M. Baseler,et al.  Circulating CXCR5+CD4+ T Follicular-Like Helper Cell and Memory B Cell Responses to Human Papillomavirus Vaccines , 2015, PloS one.

[12]  Jinfang Zhu.  T helper 2 (Th2) cell differentiation, type 2 innate lymphoid cell (ILC2) development and regulation of interleukin-4 (IL-4) and IL-13 production. , 2015, Cytokine.

[13]  Elizabeth R. Unger,et al.  Use of 9-Valent Human Papillomavirus (HPV) Vaccine: Updated HPV Vaccination Recommendations of the Advisory Committee on Immunization Practices , 2015, MMWR. Morbidity and mortality weekly report.

[14]  E. Sanders,et al.  Identification of Pertussis-Specific Effector Memory T Cells in Preschool Children , 2015, Clinical and Vaccine Immunology.

[15]  J. Cuzick,et al.  A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. , 2015, The New England journal of medicine.

[16]  M. Einstein,et al.  Comparative humoral and cellular immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18–45 years: Follow-up through Month 48 in a Phase III randomized study , 2014, Human vaccines & immunotherapeutics.

[17]  D. Dolfi,et al.  Circulating CXCR5+PD-1+ Response Predicts Influenza Vaccine Antibody Responses in Young Adults but not Elderly Adults , 2014, The Journal of Immunology.

[18]  H. D. de Melker,et al.  Immunity against poliomyelitis in the Netherlands, assessed in 2006 to 2007: the importance of completing a vaccination series. , 2014, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[19]  E. Deenick,et al.  Human T follicular helper (Tfh) cells and disease , 2014, Immunology and cell biology.

[20]  N. Wulffraat,et al.  Immunogenicity and safety of the bivalent HPV vaccine in female patients with juvenile idiopathic arthritis: a prospective controlled observational cohort study , 2013, Annals of the rheumatic diseases.

[21]  C. Meijer,et al.  Characteristics of HPV-Specific Antibody Responses Induced by Infection and Vaccination: Cross-Reactivity, Neutralizing Activity, Avidity and IgG Subclasses , 2013, PloS one.

[22]  A. Tozzi,et al.  Hepatitis B specific T cell immunity induced by primary vaccination persists independently of the protective serum antibody level. , 2013, Vaccine.

[23]  H. D. de Melker,et al.  Prevalence of genital HPV infections and HPV serology in adolescent girls, prior to vaccination. , 2012, Cancer epidemiology.

[24]  H. D. de Melker,et al.  Seroprevalence of seven high-risk HPV types in The Netherlands. , 2012, Vaccine.

[25]  G. Ogilvie,et al.  Age of recipient and number of doses differentially impact human B and T cell immune memory responses to HPV vaccination. , 2012, Vaccine.

[26]  M. Slifka,et al.  Contributions of humoral and cellular immunity to vaccine-induced protection in humans. , 2011, Virology.

[27]  C. Wheeler,et al.  Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial , 2010, BMJ : British Medical Journal.

[28]  L. Cavacini,et al.  Structure and function of immunoglobulins. , 2010, The Journal of allergy and clinical immunology.

[29]  H. T. ten Hulscher,et al.  Long-term presence of memory B-cells specific for different vaccine components. , 2009, Vaccine.

[30]  B Romanowski,et al.  Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women , 2009, The Lancet.

[31]  H. zur Hausen,et al.  Papillomaviruses in the causation of human cancers - a brief historical account. , 2009, Virology.

[32]  Nichole E Carlson,et al.  Duration of humoral immunity to common viral and vaccine antigens. , 2007, The New England journal of medicine.

[33]  Henry C Kitchener,et al.  Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial , 2007, The Lancet.

[34]  F. X. Bosch,et al.  Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions , 2007 .

[35]  Daron G Ferris,et al.  Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. , 2007, The New England journal of medicine.

[36]  K. Smith,et al.  Analysis of costimulatory molecule expression on antigen-specific T and B cells during the induction of adjuvant-induced Th1 and Th2 type responses. , 2006, Vaccine.

[37]  Allan Hildesheim,et al.  HPV-16 L1 VLP vaccine elicits a broad-spectrum of cytokine responses in whole blood. , 2005, Vaccine.

[38]  K. Smith,et al.  In Vivo Generated Th1 Cells Can Migrate to B Cell Follicles to Support B Cell Responses1 , 2004, The Journal of Immunology.

[39]  K. Smith,et al.  Inducible Costimulatory Molecule-B7-Related Protein 1 Interactions Are Important for the Clonal Expansion and B Cell Helper Functions of Naive, Th1, and Th2 T Cells 1 , 2003, The Journal of Immunology.